FDA approves first new tuberculosis in 40 years

December 31, 2012

The Food and Drug Administration says it has approved a Johnson & Johnson tuberculosis drug that is the first new medicine to fight the deadly infection in more than four decades.

The agency approved J&J's pill, Sirturo, for use with other older drugs to fight hard-to-treat .

Sirturo is the first medicine specifically designed for treating multi-drug-resistant tuberculosis. That's an increasingly common form of the disease that cannot be treated with at least two of the four primary antibiotics used to treat tuberculosis.

The standard drugs used to fight the disease were developed in the 1950s and 1960s.

Roughly one-third of the world's population is estimated to be infected with the bacteria causing tuberculosis.

Explore further: Drug-resistant TB blamed on Indian treatment flaws


Related Stories

Drug-resistant TB blamed on Indian treatment flaws

March 23, 2012

(AP) -- India's inadequate government-run tuberculosis treatment programs and a lack of regulation of the sale of drugs that fight it are responsible for the spiraling number of drug-resistant cases that are difficult to ...

Recommended for you

Can exercise be replaced with a pill?

October 2, 2015

Everyone knows that exercise improves health, and ongoing research continues to uncover increasingly detailed information on its benefits for metabolism, circulation, and improved functioning of organs such as the heart, ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

not rated yet Dec 31, 2012
This looks similar to a quinolone drug such as cipro, but it is not. Discovered by Koen Andries and his team at Janssen Pharmaceutica, Bedaquiline was described for the first time in 2004.
Bedaquiline affects the proton pump for ATP synthase, which is unlike the quinolones, whose target is DNA gyrase.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.